Multiple Sclerosis
In early June 2008, the 18th meeting of the European Neurological Society (ENS) welcomed over 3,000 neurologists and physicians from all over the world to Nice, France. Among the multitude of symposia, oral sessions and scientific programmes on the latest in the progress made in neurodegenerative diseases were presentations by leaders in the field of multiple sclerosis (MS). Noted key points discussed included new developments in research, and the concept that drug efficacy varies depending on the treatment stage: beginning treatment earlier in the course of the disease may be more beneficial. With strong evidence presented in support of initiating treatment earlier, neurologists have been offered the opportunity to protect patients against disease progression. By implementing early intervention it may be possible to improve the prognosis of this debilitating neurodegenerative disease.
Latest Developments in Multiple Sclerosis
In a symposium discussing autoimmune disorders of the nervous system, Professor Giancarlo Comi (Italy) addressed important new issues arising from recent MS research on disease prevalence, causal factors, disease evolution and MS therapy. Recent epidemiological studies have suggested an increase in the prevalence of MS in a number of European nations -Spain, 1 France, 2 Greece, 3 Germany 4 and Italy 5, 6 -particularly in the last five years. There is a trend for a nearly exclusive increase of the disease in women compared with men, says Professor Comi, attributed to lifestyle changes in women or improvements in hygiene and control of early childhood infections. 7 The role of genetics and environment as causal factors of MS continues to be debated. The genome-wide approach has identified interleukin-7 receptor alpha (IL-7 rα) and interleukin-2 receptor alpha (IL-2 rα) alleles as risk factors for developing MS. 8 There is also evidence of an association between developing MS and low exposure to sunlight and vitamin D, 9, 10 and much research is being conducted on the relationship between MS and Epstein-Barr virus (EBV) and, more recently, varicella zoster virus (VZV). EBV RNA 11 and EBV antigens 12 have been detected in a high proportion of brain tissue samples from MS patients, indicative of a role for EBV in MS immunopathology.
There is also evidence of a very strong correlation between the viral load of VZV in cerebrospinal fluid (CSF) and blood samples and the appearance of an MS attack. 13 Other research has focused on the mechanisms concerning the irreversible damage to the central nervous system (CNS) during disease progression. Not only can axonal damage and inflammation in early phases of the disease produce acute lesions, 14 but it appears that initial damage can also increase damage in positive feedback loops through the overexpression of glutamate receptors, 15 voltage-gated sodium channel (Nav)1.6 16 and calcium channels. 17 The extent of focal atrophy around a lesion has been associated with brain atrophy and loss of volume. 18 Other factors such as the duration of the inflammation, the size of the lesion and the location of the lesion have been linked to predicting the degree of persistent damage. 19 Furthermore, lesion damage has been found to evolve continuously in all phases of the disease in as little as a 12-month follow-up. 20 With such detrimental effects on the brains of MS patients, Professor Comi concluded this presentation with a call to improve treatment by increasing accessibility to new treatments and improving the ability to better apply existing therapies.
Optimising Therapy Through Earlier Treatment and Drug Selection in Different Phases of the Disease
A theme common to many of the MS presentations at the ENS was to initiate MS therapy at an earlier stage, not just when a clinically definitive diagnosis has been made. Many clinical trials have shown a dissociation between disease progression and inflammation, supporting the hypothesis that MS is primarily an inflammatory disorder and that inflammatory axonal injury underlies the formation of new lesions and axonal degeneration. 21 By protecting against inflammation, it may then be possible to slow progression in MS, and in turn reduce the degree of tissue injury and degeneration of the nervous system. According to Professor Alistair Compston (UK) in his talk about the rationale for early treatment, offering immunological therapies early in the course of the disease -before the cascade of events leading to axonal degeneration is irreversibly established -may be most beneficial in preventing sustained disability and disease progression. Indeed, early treatment has been shown to limit axonal damage and protect against irreversible nervous damage and ensuing disability. 22 
Treatment After a Clinically Isolated Syndrome
Patients who have experienced a clinically isolated syndrome (CIS) are at high risk of developing clinically definite MS (CDMS). Epidemiological studies and clinical trials have shown that approximately 85% of CIS patients are diagnosed with MS within two years. 23 It is at this early stage of the disease that treatment should be initiated, elaborated Professor Comi, with evidence from magnetic resonance imaging (MRI) studies showing brain atrophy and decreased brain volume in the very early stages of MS. 24, 25 All three clinical trials testing the use of interferon beta formulations 
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In her presentation entitled 'Earlier is better -the importance of MS treatment', Dr Mar Tintoré (Spain) explained that a first neurological event warrants early treatment because of the events that occur early in the disease course. Early axonal damage is correlated to inflammation and may be irreversible, and atrophy appears soon after the occurrence of a clinically isolated syndrome (CIS). 14, 25 Early factors have a significant impact in the long term; evidence from natural history studies negatively correlates the number of attacks in the early years of the disease with the time it takes to reach greater disability and disease severity, 73 and the time interval between the first and second attacks has proved to be a major clinical factor in predicting long-term disability. 74 Magnetic resonance imaging (MRI) parameters have also proved useful in assessing the risk of multiple sclerosis (MS) disease progression; CIS patients followed for a median of seven years showed that those who developed new T2 lesions faced an increased risk of progressing to clinically definite MS (CDMS). Furthermore, increases in lesion volume are correlated with greater long-term disability. 75 Indeed, the CHAMPS and PreCISe studies in monofocal patients and the ETOMS and BENEFIT studies in mono-and multifocal patients have all shown that early treatment can significantly delay the development to CDMS compared with placebo (see Figure 1) .
Another important message raised in recent years is that drug efficacy may vary depending on the disease phase. In the CIS stage, drug efficacy is around 50%, but drops to 30% for patients in the relapsing-remitting phase and continues to decrease through the disease course (see Figure 2 ). This key concept has been seen with a number of different drugs, says Dr Tintoré, with the same drug having greater efficacy when introduced earlier. If physicians delay in treating patients, then not only are patients at greater risk of earlier disease progression and disability, but when they finally receive disease-modifying therapies they will experience much less efficacy.
A similar emphasis on early treatment was expressed by Professor David Bates (UK). Initial inflammation of the nervous system occurs early in the disease, leading to demyelination and subsequent axonal loss. This inflammation may occur in a pre-clinical way, where it is unnoticed until a patient experiences a clearly eloquent attack. Throughout the disease, a majority of patients will experience a gradual loss of brain tissue and continued and increasing damage to the axons, with progressive deterioration in cognition and memory, all the while showing a gradual increase in damage on the MRI scan (see Figure 3) . Because the available MS treatments are predominantly anti-inflammatory, it follows that their greatest effect will take place at the beginning of the disease course when the nervous system is inflamed. Although the available MS therapies do show an effect in the later courses of the disease, their ability to prevent subsequent deterioration is unlikely. ■ to CDMS (see Table 1 ), prolonged time to a second attack and reduced brain MRI activity. [26] [27] [28] Furthermore, extensions of these studies with at least three years of follow-up confirm that CIS patients who received early therapy continued to benefit significantly in terms of preventing a second attack. 29, 30 The BENEFIT trial revealed that even as little as three years of early treatment can significantly reduce the risk (by 40%) of confirmed expanded disability status scale (EDSS) progression compared with patients in whom treatment with interferon beta-1b (Betaferon, Bayer Schering Pharma) was delayed,. 29 Furthermore, the prospectively planned follow-up study showed that after three years interferon beta therapy applied early -at the time of the first episode suggestive of MS -showed significant ability in preventing the conversion from CIS to CDMS in all studies analysed, with benefits persisting through two years of treatment. 33 So, should all patients with a CIS be treated immediately following the first neurological episode? Not necessarily, says Professor Comi, as it depends largely on the patient's clinical presentation. Rather, the following prognostic factors -as determined from ETOMS, CHAMPS, BENEFIT and PreCISe -can help to predict which CIS patients are at increased risk of early conversion to CDMS:
• ≥9 T2 lesions;
• >1 gadolinium-enhancing (Gd+) lesion;
• multifocal presentation;
• higher clinically and MRI-measured disease severity at onset, with a longer pre-clinical phase and/or more aggressive disease course; and
• ongoing brain activity in the MRI indicative of inflammation.
According to Professor Comi's personal recommendations for patients with a first attack and brain MRI suggestive of MS, early treatment should be initiated for those exhibiting one or more negative prognostic factor, whereas those lacking negative prognostic factors should be carefully monitored and given repeat MRIs, with therapy being initiated on evidence of temporal dissemination. Patients who have suffered an attack but retain otherwise normal brain MRI or an MRI scan atypical of MS are at low risk of conversion to CDMS or disability, and should undergo annual MRI scans. 34 However, Professor Comi does stress that he disagrees with the generalisation that CIS patients should not be treated with immunomodulatory drugs because of the chance that a subgroup may have a benign disease course. The reason for this is that the purpose of treating CIS patients is to anticipate and prevent potential damage; this is significant as 85-94% of untreated CIS patients have new attacks or lesion formations within two years of the original clinical event. 23, 26, 27 Unfortunately, there are still some European countries that do not reimburse treatment for CIS patients, and many of these affected patients are denied access to highly effective therapies.
Treatment of Clinically Definite Multiple Sclerosis
The past 15 years have seen an expansion in the therapeutic armamentarium against MS from just interferon beta-1b alone to a small group of immunosuppressants and immunomodulatory drugs, and although this continually growing collection provides treatment options for patients with MS, it has also greatly complicated the selection of any specific drug for treatment at a given disease stage. However, stresses Professor Christian Confavreux (France), initiating treatment as soon as possible is essential -and the earlier, the better.
Although it may prove useful to follow official guidelines such as those provided by the European Federation of Neurological Societies, 35 the patient's disease phase must also be assessed as the initial step in selecting a treatment, accounting primarily for the clinical activity, with MRI activity as secondary criterion. It is known that the currently available treatments of interferon beta and glatiramer acetate can improve patient outcome by reducing the rates of relapse frequency and MRI activity. However, longterm efficacy in delaying disability remains uncertain. Drawing on the data from the head-to-head comparisons Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND), 36 Rebif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) 37 and Betaseron vs Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints (BECOME), 38 Professor Confavreux concluded that the similarities in efficacy and long-term safety exhibited by the interferon betas and glatiramer acetate qualifies them as prime candidates in the first-line treatment of active forms of RRMS.
The efficacy of natalizumab is even greater, with a 68% reduction in relapse rate and 83% reduction of new or enlarging T2 lesions, 39 but it is indicated as a second-line therapy for RRMS patients who have failed treatment with interferon beta or glatiramer acetate, or for treatmentnaïve patients with rapidly evolving severe MS. 40 However, the association with serious and fatal infection such as progressive multifocal leukoencephalopathy (PML) and possible neoplastic complications requires close monitoring upon prescribing natalizumab.
Immunosuppressive third-line therapies such as mitoxantrone or cyclophosphamide are recommended for severe aggressive MS or disease breakthrough.
Deciding on a treatment is rarely as simple and clear-cut as following recommendations, however; MS is a long-term, chronic and very heterogeneous disease, with disease activation presenting differently between patients. Patient characteristics, such as age at onset and apparent disease severity, and clinical factors, such as drug efficacy, safety and tolerability, need to be considered together in assessing treatment options;
ultimately, any chosen therapy should have an extremely important effect on the disease pattern and future prognosis of MS.
Induction Therapy in Multiple Sclerosis
There are cases where patients continue to experience frequent relapses and disease progression despite disease-modifying therapy.
Combination therapy is typically designated for treatment failures, and Gd+ lesions one year after immunosuppression was initiated, with good tolerance and no adverse events. 44 Data from a one-year follow-up are expected. However, there is a caveat, warns Dr Lisak, because even short-term use of immunosuppressants may pose long-term risks, including oncogenesis, 45 infertility and congestive heart failure, depending on the choice of antisuppressant.
Similar to the problem of identifying which patients qualify for early MS treatment, those with suboptimal responses also need to be identified for treatment, be it by switching between immunomodulatory agents or switching from immunomodulation to immunosuppression; so far, clinical criteria, MRI criteria and biomarkers have been the most help in selecting patients for induction therapy. 46 Dr Lisak concluded that a composite using criteria indicative of highly active disease that clearly warrants induction with immunosuppressive therapy is necessary, and presented provisional recommendations put together by himself and his colleague Dr Omar Khan (US). These recommendations state that observing any three or more of the following criteria in a patient should compel the clinician to initiate immunosuppressive therapy:
• >2 relapses in the past 12 months requiring corticosteroid treatment;
• recurrent brain stem or spinal cord relapses;
• EDSS >3.0 within three to six months following the last relapse;
• ≥3 Gd+ lesions that are >3mm in size on a single scan;
• ≥3 new T2 lesions in the past 12 months; and
• any evidence of atrophy.
Diagnosing Benign Multiple Sclerosis
Designating a case of MS as benign confers a favourable course of MS in which such patients experience mild or no disability after the initial clinical onset. However, an increasing amount of emerging data has instigated great debate as to how benign MS can be diagnosed with absolute certainty, and whether or not such a condition actually exists. The problem with this label is that patients with benign MS are under the impression that their symptoms will not worsen, and as a result will be unlikely to seek out the same level of medical attention as patients who have been diagnosed with CDMS. Moreover, for benign patients who become nonbenign over time, this poses a great loss in terms of health and protection against disability that could otherwise have been prolonged or delayed with early treatment.
Patients with benign MS experience fewer lesions than patients with early RRMS. 47 However, lesion load has been found to be higher in benign patients than in those with early RRMS 48 and those with non-disabling RRMS. 49 Furthermore, no significant difference could be found in normal brain volume and, by association, neuroaxonal brain viability between benign and early RRMS patients. 49 The researchers of these studies argue that patients with benign MS experience a relative sparing of cortical damage, which then bestows upon them favourable clinical disease courses, but the presence of lesions in benign patients and the fact that these patients have an increase in lesion loads cannot be ignored. Cognitive dysfunction in benign MS is also associated with significantly more severe damage to the corpus callosum, with significantly higher lesion load compared with benign patients without cognitive impairment. 50
Updates on Efficacy in Recommended Multiple Sclerosis Therapies
Prior to prescribing any sort of treatment to a patient, drug efficacy, safety and tolerability are all factors that must be carefully considered. This section of the report will focus on the advances and recent research that have been made available in these areas, as discussed at the ENS, as well as a special focus on the up-and-coming drugs in development.
Conclusive comparisons between the various therapies available for MS have been rather difficult because to date there has been no single study that has directly compared them all together in terms of efficacy and safety in a head-to-head manner. However, direct comparisons have shown that interferon beta-1b administered every other day has greater efficacy than a once-weekly dose of interferon beta-1a, with significant differences in the number of patients who remained relapse-free or experienced a delay to CDMS. 51 High-dose interferon beta-1a given three times a week has a greater advantage over weekly dosage in terms of the percentage of patients who are relapse-and T2-lesion-free and the number of active lesions. 52 Other comparisons have shown a similar efficacy between interferon beta-1b and glatiramer acetate: the BECOME study showed that treatment with interferon beta-1b led to fewer permanent black holes developing from enhancing lesions than glatiramer acetate, although no significant difference was observed in terms of ability to reduce MS activity and the mean number of combined active lesions. 38 Similarly, the REGARD study found no significant difference between the treatments in the number and change in volume of active lesions or the time to the first relapse. 37 Data from the BEYOND study presented at the ENS comparing the efficacy, safety and tolerability of interferon beta-1b 250mcg, interferon beta-1b 500mcg and glatiramer acetate 20mg daily in RRMS patients over a period of 24 months showed no significant differences between any of the treatment arms in relapse risk, the number or volume of T1 transforming discovery into care', Dr Kieseier spoke about the importance of initiating treatment at diagnosis, in which a 'window of opportunity' exists to offer neurologists the chance to possibly maintain an isolated syndrome and avoid future progression to secondary progression or chronic illness (see Figure 4 ). All patients in the CHAMPS study received interferon beta-1a intramuscularly, but those randomised to receive immediate treatment from study onset rather than placebo and delayed interferon beta-1a experienced greater benefits with reduced risk of progression to CDMS and annualised relapse rate over five years. 27, 30 Additionally, interferon beta-1a has been shown to decrease the mean number of MRI lesions, brain atrophy 80 and cognitive dysfunction. 81 Dr Kieseier noted that patients who receive delayed treatment never quite catch up with those receiving early treatment in terms of experiencing the same benefits.
The next speaker in this symposium, Dr Norman Putzki (Germany), presented an argument supporting the role of natalizumab as an anti-inflammatory drug in MS. With the drug indicated for patients with more active disease, a sub-analysis of highly active patients who were placebo-treated in the AFFIRM trial showed that natalizumab retained similar efficacy in active disease to that seen in patients who received natalizumab earlier, and in so doing was able to reduce the annualised relapse rate of these highly active patients. Risk reduction of disease progression over two years decreased by more than 50%, and this effect was observed in highly active patients as well. 39 Crucial to demonstrating the relative difference between receiving and not receiving treatment, according to Dr Putzki, is the fact that natalizumab increased the proportion of patients free of clinical or MRI disease activity by fivefold, regardless of baseline severity. 82 Cases of progressive multifocal leukoencephalopathy (PML) have previously been reported for natalizumab/interferon beta-1a combination therapy, which led to the temporary withdrawal of natalizumab from the market. One study suggested that the likelihood of PML over 18 months of treatment would be roughly one in 1,000 patients. 83 However, since the conclusion of the ENS, two new and separate cases of PML in patients receiving natalizumab monotherapy over a span of approximately 14 and 17 months, respectively, has emerged. 84 With more than 43,000 patients who have been exposed to natalizumab, 85 these occurrences of PML remain in the predicted frequency of one incidence in every 1,000 patients. ■ 
From Clinical Trials to Clinical Practice
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Gd+ lesions or T1 black holes or brain volume. 53 A similarly high proportion of patients in each arm were free from disease activity. 54 However, T2 lesion volume change and cumulative volume were lower in groups using interferon beta-1b compared with glatiramer acetate, suggesting that there may be different effects on the overall disease burden depending on treatment. 53 Natalizumab has been recommended as second-line therapy for patients who continue to progress while receiving the first-line disease-modifying These safety issues and the lack of information regarding long-term use has led to reservations over using the drug outside of clinical research.
Although mitoxantrone has been suggested for aggressive forms of MS, it has also been associated with a risk of oncogenesis. The prevalence of acute myeloid leukaemia (AML) is significantly increased in MS patients who receive mitoxantrone treatment, and appears to occur in younger patients.
No apparent correlation was found between previous MS treatments and cumulative mitoxantrone dose with the risk of developing AML. 45 
The Effect of Tolerability on Adherence and Quality of Life
For a patient to maintain adherence and reap the complete benefits of their disease-modifying therapy, their treatment must be tolerable. MS patients often experience headaches, and headaches related to treatment with interferon beta that were independent of flu-like symptoms have recently been found to be more frequent than previously reported. Although not a contraindication to therapy with interferon beta, physicians are suggested to monitor patients for headaches and to adjust therapy if the frequency increases. 56 The BENEFIT studies have demonstrated good tolerability to interferon beta-1b in patients with CIS, with a high adherence rate after three years (>73.3%) and a large proportion (>89.3%) of patients choosing to continue therapy in the follow-up study. 57 A comparison of tolerability between interferon beta-1b 250mcg and glatiramer acetate in the BEYOND study showed that patients treated with interferon were more likely to experience flu-like symptoms, although the incidence of this adverse effect decreased with time. In contrast, injection-site reactions were commonly reported by patients receiving glatiramer acetate. 58 The new formulation of interferon beta-1a (Rebif new formulation [RNF]), produced without foetal bovine serum and human serum albumin, has
shown reduced immunogenicity compared with the current formulation in patients with relapsing MS. 59, 60 The incidence of serious adverse events was similar to that seen in data from the Evidence of Interferon Dose-response:
European North American Comparative Efficacy (EVIDENCE) and REGARD studies, although patients were more likely to have flu-like symptoms with RNF. However, RNF had fewer patient-reported injection-site reactions and feelings of depression. The overall safety and tolerability profile of RNF relative to the current formulation of interferon beta-1a is proposed to influence treatment adherence. 60 As with any chronic life-long disease, adherence to drug therapy is a major determinant of the success of the disease-modifying therapy, and this concept is no different in MS. Adherence and relapse rate are closely associated: one study has shown that patients who refused to adhere to treatment for over 90 days face a significantly increased risk of severe MS relapse compared with patients with shorter or no gaps in drugmodifying treatment. 61 Studies have also shown that adherence varies depending on the drug in question. Adherence in the BEYOND trial was high in all groups, but a slightly higher number of patients treated with interferon beta-1b 250mcg (82%) saw the study through to completion compared with those treated with high-dose interferon beta-1b 500mcg (73%) or glatiramer acetate (78%). 36, 58 Certainly, the results from clinical trials with respect to adherence are an area to be considered by physicians when prescribing medications for patients, and the subject of adherence is an important one, as drug compliance is closely linked to the patient's quality of life -the efficacy of a drug is irrelevant if patients exhibit poor compliance, for example, due to bad adverse effects or low tolerance, which ultimately leads to disease progression and poor patient outcome. However, quality of life is not solely dependent on drug use and compliance: one study assessed a cohort of Polish subjects with MS to determine the most important factors affecting quality of life and found depression, level of disability, fatigue and marital status to be the strongest predictors of quality of life. 62 In the Does it work, though? A large-scale analysis examining the adherence of over 4,000 patients enrolled in the BETA nurse programme in the US saw high rates in favour of the patients who had contact with a BETA nurse compared with the historical cohort who did not after 13 months (88 versus 63%) (see Figure 6 ). 88 The new Betaferon to name a few -and with the exception of oral cladribine, which has a short-course intermittent dosing regimen, these drugs require a daily or several-times-daily dosing regimen (see Table 2 70 The CD52-specific monoclonal antibody alemtuzumab (Bayer/Genzyme), which targets lymphocytes, has been compared with high-dose interferon beta-1a (Rebif) in the phase II CAMMS223 study treating patients with RRMS. The study showed that at the three-year follow-up the antibody was more effective at suppressing relapses and disability in patients than the interferon, with patients in the former group experiencing a 73% reduction in risk of relapse (p<0.0001) and a 70% reduction in risk of sustained accumulation of disability (p<0.0001). 71 Subgroup analyses found the treatment effects of alemtuzumab to be consistent across sex, age, race and country, indicating that these findings were independent of patient baseline demographics.
An Emergence of Oral Therapies
Some of these drugs being developed and studied are oral compoundsa class of MS therapies that is amassing increasing interest from researchers and physicians alike. One example of these new oral drugs is laquinimod (Teva Pharmaceutical); MRI data from an extension of the double-blind, randomised, placebo-controlled phase IIb study have
shown that patients benefited in terms of reductions in the mean number of T1 lesions when switching to laquinimod from placebo, although no significant difference in annualised relapse rate could be discerned. 72 
Summary
The are in development as well; of these, there is great anticipation for the oral therapies being tested, where it is hoped that the advantage of convenience over the current parenteral options will also help to maintain good adherence levels. ■
